Abstract
Multiple sclerosis (MS) is a progressive neurodegenerative disease affecting myelin and axons, which is perpetuated by autoreactive lymphocytes and other inflammatory cell types. Because of the multifactorial nature of this disease, therapies targeting a single process may not be sufficient to halt its progression. VIP and PACAP are two neuropeptides shown to regulate multiple aspects of innate and adaptive immunity, and can also act independently on neural cells to promote their survival and regeneration. Animal studies have proven the efficacy of these peptides for the treatment of several models of neural inflammatory disorders, including those which, like MS, have major Th1/Th17 components. In this review, the immunomodulatory actions of VIP and PACAP will be discussed, with particular emphasis on their potential significance in MS.
Keywords: VIP, PACAP, multiple sclerosis, EAE, neuroimmunomodulation, neuropeptides, immunoprivilege, dexamethasone, lipopolysaccharide, ligand flagellin, orchestrate, microglia, granzyme B, tolerogenic, encephalomyelitis, erythroleukemia, mitogen, myelin, glatiramer acetate
Current Pharmaceutical Design
Title: Immunomodulatory Roles of VIP and PACAP in Models of Multiple Sclerosis
Volume: 17 Issue: 10
Author(s): Catalina Abad and James A. Waschek
Affiliation:
Keywords: VIP, PACAP, multiple sclerosis, EAE, neuroimmunomodulation, neuropeptides, immunoprivilege, dexamethasone, lipopolysaccharide, ligand flagellin, orchestrate, microglia, granzyme B, tolerogenic, encephalomyelitis, erythroleukemia, mitogen, myelin, glatiramer acetate
Abstract: Multiple sclerosis (MS) is a progressive neurodegenerative disease affecting myelin and axons, which is perpetuated by autoreactive lymphocytes and other inflammatory cell types. Because of the multifactorial nature of this disease, therapies targeting a single process may not be sufficient to halt its progression. VIP and PACAP are two neuropeptides shown to regulate multiple aspects of innate and adaptive immunity, and can also act independently on neural cells to promote their survival and regeneration. Animal studies have proven the efficacy of these peptides for the treatment of several models of neural inflammatory disorders, including those which, like MS, have major Th1/Th17 components. In this review, the immunomodulatory actions of VIP and PACAP will be discussed, with particular emphasis on their potential significance in MS.
Export Options
About this article
Cite this article as:
Abad Catalina and A. Waschek James, Immunomodulatory Roles of VIP and PACAP in Models of Multiple Sclerosis, Current Pharmaceutical Design 2011; 17 (10) . https://dx.doi.org/10.2174/138161211795589364
DOI https://dx.doi.org/10.2174/138161211795589364 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Diabetic Cardiomyopathy: Clinical and Metabolic Approach
Current Vascular Pharmacology Strategies for Enhancing Progenitor Cell Mobilization and Function in Diabetes
Current Vascular Pharmacology Potential Therapeutic Effects of Na+/Ca2+ Exchanger Inhibition in Cardiac Diseases
Current Medicinal Chemistry Myocardial Perfusion SPECT Imaging in Patients after Coronary Revascularization
Vascular Disease Prevention (Discontinued) Stem Cells: In Sickness and in Health
Current Stem Cell Research & Therapy Are the Antioxidant Properties of Carvedilol Important for the Protection of Cardiac Mitochondria?
Current Vascular Pharmacology In Vivo Delivery of Morpholino Oligos by Cell-Penetrating Peptides
Current Pharmaceutical Design Metabolic Reprogramming of Human Cells in Response to Oxidative Stress: Implications in the Pathophysiology and Therapy of Mitochondrial Diseases
Current Pharmaceutical Design Sympathetic Overactivity in Hypertension and Cardiovascular Disease
Current Vascular Pharmacology Patent Selections
Recent Patents on Cardiovascular Drug Discovery Targeting the Arrhythmogenic Substrate in Atrial Fibrillation: Focus on Structural Remodeling
Current Drug Targets Xanthine Oxidase Inhibitors the Unappreciated Treatment for Heart Failure
Cardiovascular & Hematological Disorders-Drug Targets Targeting the Fatty Acid Transport Proteins (FATP) to Understand the Mechanisms Linking Fatty Acid Transport to Metabolism
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Gene Therapy Approaches to Ataxias
Current Gene Therapy Combating Obesity by Targeting Nuclear Receptors
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents HIF Prolyl-4-hydroxylase Interacting Proteins: Consequences for Drug Targeting
Current Pharmaceutical Design How to Make a Non-Antigenic Protein (Auto) Antigenic: Molecular Complementarity Alters Antigen Processing and Activates Adaptive-Innate Immunity Synergy
Anti-Cancer Agents in Medicinal Chemistry Does Oral Metoprolol have Any Effect on the Functional Parameters and Perfusion Defects of the Left Ventricle?
Current Medical Imaging Pathophysiology, Diagnosis and Clinical Management of Hepatorenal Syndrome: From Classic to New Drugs
Current Vascular Pharmacology Potential Role of Rho Kinase Inhibitors in Combating Diabetes-Related Complications Including Diabetic Neuropathy-A Review
Current Diabetes Reviews